Durham, NC—July 1, 2014— NeuroCog Trials, Inc. announces that it has begun work supporting a major pharmaceutical company clinical trial to assess performance- based skills assessment in patients with major depression. The trial will examine the effects of active drug treatment versus placebo on cognitive and functional outcomes across a variety of countries and cultures.
Richard Keefe, Ph.D., Founder and CEO of NeuroCog Trials, said, “We are tremendously excited to be a part of this program. Patients with major depression can manifest significant deficits in cognitive and functional outcomes that do not respond to traditional anti-depressant medications. Treatments that can improve this devastating component of the illness are sorely needed. Reliable assessment of cognition and performance-based skills is crucial to clinical trials in this area of research. The assessment of functioning across different cultures and geographical regions can be particularly challenging, and we are delighted that our international experience and expertise is being recognized. We are gratified that we have been chosen to train raters and assure data quality for this study.”